CTRI/2021/01/030675尚未招募4 期
An ambispective cohort study to assess the efficacy of immunosuppressive therapy in systemic sclerosis associated interstitial lung disease.
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with a diagnosis of systemic sclerosis as per the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria, irrespective of their gender, will be included in the study. They may have either diffuse cutaneous or limited cutaneous systemic sclerosis.
- •2. Age >=18 years.
- •3. Patients with the following evidence of pulmonary involvement:
- •a)% predicted FVC less than or equal to 70% and/ or
- •b)HRCT chest showing involvement of more than or equal to 20% of lung area with interstitial lung disease
- •4.Patients already on immunosupressives, who have a baseline and a follow-up PFT and HRCT available
排除标准
- •1. Patients with overlap syndrome.
- •2. Diagnosis of clinically significant resting pulmonary hypertension requiring treatment diagnosed on echocardiography (defined as tricuspid regurgitation velocity more than 4m/s, equivalent to estimated pulmonary artery systolic pressure of 64 mm Hg) while evaluation of the patient during study.
- •3. Evidence of uncontrolled congestive heart failure, unstable ischemic heart disease, history of pulmonary embolism, or cardiac arrhythmia requiring chronic anticoagulation.
- •4. FVC less than or equal to 15% at baseline.
- •5. More than 50% area of lung showing fibrosis on HRCT chest at baseline.
- •6. Hematologic abnormality at screening including:
- •a) Leukopenia (white blood cells [WBC] < 4.0x103/µl).
- •b) Thrombocytopenia (platelet count < 150.0x103/µl).
- •c) clinically significant anemia (hemoglobin < 7 g/dl).
- •d) Participants with an identified and correctable etiology will be eligible if repeat testing shows values greater than the above mentioned cut-off.
- •7. A diagnosis of chronic liver disease or abnormal baseline liver function tests (total bilirubin or liver enzymes, alanine aminotransferase and aspartate aminotransferase > 2.0 times the upper normal limit).
- •8. Serum creatinine >2.0mg/dl
- •9. Pregnancy and/or breast feeding
- •10. If of child bearing potential (a female participant less than 55 years of age who has not been postmenopausal for more than 5 years or who has not had a hysterectomy and/or oophorectomy), failure to employ reliable means of contraception.
- •11. Prior use of oral or intravenous cyclophosphamide, MMF, azathioprine or other putative disease modifying medications in last 3 months (assessed at baseline).
- •12. Current use, or use within the 30 days prior to their baseline visit, of prednisone (or equivalent) in dose of 40 mg/day
- •13. Active infection (Hepatitis B, Hepatitis C, tuberculosis, HIV) whose management would be compromised by immunosuppression.
研究者
相似试验
招募中
Unknown
A study to evaluate the effect of widening of upper airway on lower airway obstructioCTRI/2023/06/054248All India Institute of Medical Sciences, New Delhi
进行中（未招募）
Unknown
Study to Evaluate the Effectiveness and Safety of PravastatiEndocrine, nutritional and metabolic diseasesKCT0009248Daiichi-Sankyo Korea8,464
已完成
不适用
Retrospective cohort study for evaluation of efficacy of a newly developed dilator for endosonography-guided biliary drainageMaligant biliary obstructionJPRN-UMIN000020772Sendai City Medical Center28
招募中
不适用
Retrospective cohort study of evaluating the efficacy of ICG fluorescence imaging on anastomotic leakage in laparoscopic surgery of colon cancerColon cancerJPRN-UMIN000039977Yokosuka kyosai hospital800
招募中
不适用
Evaluation of PC+ 2.0 in Blue Care according to Triple AimNL-OMON29253Maastricht Universitair Medisch Centrum (MUMC+)3,660